Cited by 770Immune cells in cancerCancer Immunotherapy and BiomarkersChemokine receptors and signaling

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Open access

Highfill, Steven L., Cui, Yongzhi, Giles, Amber J., Smith, Jillian P., Zhang, Hua, Morse, Elizabeth, Kaplan, Rosandra N., Mackall, Crystal L.·2014·Science Translational Medicine

DOI 10.1126/scitranslmed.3007974PMC PMC6980372

Open this paper in CoChat — free account

Abstract

Preventing trafficking of myeloid-derived suppressor cells to the tumor site enhances the efficiency of checkpoint blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3007974

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“Signaling of PD1 on T cells via PD-L1 (B7-H1) or PD-L2 (B7-DC) inhibits T cell receptor–mediated activation by recruitment of the SHP2 phosphatase (2).”
Background
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Combination regimens appear to be even more potent with response rates of 53% in metastatic melanoma (22).”
Background
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“These results are consistent with previous reports demonstrating that GrMDSCs at the tumor site are highly dependent on migration from the BM or spleen and undergo minimal proliferation within the tumor bed (13).”
BackgroundResult
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261

Show all 50 references

Sorted by citations

Items 501–600 of 770

Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression
Li, G., Li, D., & Zhu, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1662145 · Cited by 17
Interplay between the Human Microbiome and Biliary Tract Cancer: Implications for Pathogenesis and Therapy
Ye, C., Dong, C., Lin, Y., Shi, H., & Zhou, W. (2023) · Microorganisms · doi:10.3390/microorganisms11102598 · Cited by 14
“Recent studies have illuminated the potential of targeting MDSCs in other cancers to activate anti-tumor immune responses and amplify the effectiveness of ICTs [71,72].”
Background
Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment
Masui, H., Kawada, K., Itatani, Y., Hirai, H., Nakanishi, Y., Kiyasu, Y., Hanada, K., OKAMOTO, M. T., Hirata, W., Nishikawa, Y., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02710-x · Cited by 15
Association of Chemokines and Chemokine Receptor Expression with Monocytic-Myeloid-Derived Suppressor Cells during Tumor Progression
Seo, E., Namgung, J. H., Oh, C.-S., Kim, S., & Lee, S. H. (2018) · Immune Network · doi:10.4110/in.2018.18.e23 · Cited by 14
“Also, in tumor tissue, MDSCs are believed to play an important role in inhibiting immune responses by T cells and natural killer cells, and elevated MDSC infiltration is correlated with a poor prognosis and resistance to therapy (27-30).”
Background
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
Huang, R., Bi, Z., Hu, S., Zhang, Q., Su, X., & Zhang, W. (2023) · Biomarker Research · doi:10.1186/s40364-023-00478-5 · Cited by 15
“For MDSCs, gemtuzumab can deplete intratumoral MDSCs, and the CXCR2 antagonist can block migration of MDSCs into tumors [139, 140].”
Background
Can Organoid Model Reveal a Key Role of Extracellular Vesicles in Tumors? A Comprehensive Review of the Literature
Zhang, Y., Lu, A., Zhuang, Z., Zhang, S., Liu, S., Chen, H., Yang, X., & Wang, Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s424737 · Cited by 14
Why the Outcome of Anti‐Tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers
Wang, J. H. (2020) · BioEssays · doi:10.1002/bies.202000024 · Cited by 14
Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy
Innamarato, P., & Pilon‐Thomas, S. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104277 · Cited by 12
“CCR2 and CXCR2 are key chemotactic receptors for M-MDSCs and PMN-MDSCs, respectively [47, 104, 105].”
Background
C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1)
Wan, Y., Ge, K., Zhou, W., Lu, J., Jia, C., & Zhu, H. (2021) · Biological Chemistry · doi:10.1515/hsz-2020-0328 · Cited by 13
New Discovery of Myeloid-Derived Suppressor Cell’s Tale on Viral Infection and COVID-19
Park, S., Nam, D., Seong, H. C., & Hahn, Y. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842535 · Cited by 14
Adoptive Cell Therapy for Sarcoma
Mata, M., & Gottschalk, S. M. (2015) · Immunotherapy · doi:10.2217/imt.14.98 · Cited by 14
Claudin-12 Deficiency Inhibits Tumor Growth by Impairing Transendothelial Migration of Myeloid-Derived Suppressor Cells
Cao, H., Ni, C., Han, L., Wang, R., Blasig, R., Haseloff, R. F., Qin, Y., Lan, J., Lou, X., Ma, P., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3896 · Cited by 13
Myeloid-derived suppressor cells in head and neck squamous cell carcinoma
He, J.-Y., Huo, F., Tang, H., Liu, B., & Bu, L. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.11.002 · Cited by 14
Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products
Calderon, J. J., Prieto, K., Lasso, P., Susana Fiorentino, G., & Barreto, A. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00681-0 · Cited by 15
“A second therapeutic approach involves using anti-CXCR2 or CCR2 monoclonal antibodies to reduce MDSCs infiltration in the TME, which have shown some effectiveness in murine models (Draghiciu et al. 2015; Highfill et al. 2014; Zeng et al. 2019).”
BackgroundMethod
Candida -induced granulocytic myeloid-derived suppressor cells are protective against polymicrobial sepsis
Esher, S. K., Harriett, A. J., Lilly, E. A., Fidel, P. L., & Noverr, M. C. (2023) · mBio · doi:10.1128/mbio.01446-23 · Cited by 12
“In cancer models, the migration of MDSCs to tumor sites is driven by the chemokine receptor CXCR2 in response to CXCL1/CXCL2 (18, 19).”
Background
Targeting Myeloid-Derived Suppressor Cell Trafficking as a Novel Immunotherapeutic Approach in Microsatellite Stable Colorectal Cancer
Johnson, B. (2023) · Cancers · doi:10.3390/cancers15225484 · Cited by 14
Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer
Tang, R., Wang, H., & Tang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332814 · Cited by 13
Listeria-vectored cervical cancer vaccine candidate strains reduce MDSCs via the JAK-STAT signaling pathway
Zhang, Y., Yao, L., Ou, Q., Chen, M., Tian, S., Tang, J., Li, R., Liang, Q., Chen, Z., & Wang, C. (2024) · BMC Biology · doi:10.1186/s12915-024-01876-3 · Cited by 12
“The enrichment of Treg and MDSCs at tumor sites is associated with poor prognosis in tumor patients, and a decrease in the proportions of Treg and MDSCs serves to increase antitumor immunity [14–17].”
Background
Targeting anticancer immunity in melanoma tumour microenvironment: unleashing the potential of adjuvants, drugs, and phytochemicals
Wang, J., Wang, Y., & Jiang, X. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2384071 · Cited by 12
Unraveling the tumor microenvironment of esophageal squamous cell carcinoma through single-cell sequencing: A comprehensive review
Qi, L., Wang, J., Hou, S., Liu, S., Zhang, Q., Zhu, S., Liu, S., & Zhang, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189264 · Cited by 15
The cellular and molecular mediators of metastasis to the lung
Cucanic, O., Farnsworth, R. H., & Stacker, S. A. (2022) · Growth Factors · doi:10.1080/08977194.2022.2087520 · Cited by 13
“More specifically, it was concluded that epigenetic modifiers, such as LD-AET with CCR2-antagonists, in combination with tumour resection, may mitigate the migration and function of MDSCs in the lung PMN (Lu et al. 2020; Highfill et al. 2014).”
Background
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer
Villaruz, L. C., Blumenschein, G. R., Otterson, G. A., & Leal, T. A. B. (2023) · Cancer · doi:10.1002/cncr.34683 · Cited by 12
“…rhabdomyosarcoma, an anti-CXCR2 monoclonal antibody reduced MDSC trafficking to tumor cells and enhanced the antitumor activity of PD-1 inhibition 110 ; results of a recently completed phase 1 trial of a CXCR2 antagonist (QBM076) with a PD-1 inhibitor in advanced solid tumors are awaited…”
Background
Pancreatic Cancer: Planning Ahead for Metastatic Spread
Stromnes, I. M., & Greenberg, P. D. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.013 · Cited by 12
“They tested this hypothesis by combining a CXCR2 inhibitor with an anti-PD1 antibody in KPC mice with end-stage, palpable disease, an approach that has shown therapeutic benefit in other cancer models (Highfill et al., 2014).”
Method
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC
Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.08 · Cited by 10
Mechanisms of Resistance to PD-1 Checkpoint Blockade
Moser, J. C., & Hu‐Lieskovan, S. (2020) · Drugs · doi:10.1007/s40265-020-01270-7 · Cited by 11
PDX Models: A Versatile Tool for Studying the Role of Myeloid-Derived Suppressor Cells in Breast Cancer
Gjerstorff, M. F., Traynor, S., Gammelgaard, O. L., Johansen, S., Pedersen, C. B., Ditzel, H. J., & Terp, M. G. (2022) · Cancers · doi:10.3390/cancers14246153 · Cited by 11
Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome
Zou, R., Wang, Y., Ye, F., Zhang, X., Wang, M., & Cui, S. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02637-2 · Cited by 11
“On the contrary, the loss of MDSCs within the tumor could restore the effectiveness of PD-1 blockade [61, 62].”
Background
Immuno-onco-metabolism and Therapeutic Resistance
Mir, M. A., Aisha, S., Nisar, S., Qayoom, H., & Mehraj, U. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_3 · Cited by 11
Chemokine CCL5 immune subtypes of human liver cancer with prognostic significance
Xia, Y., Zhou, L., Yang, H., & Yu, D. C. W. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109372 · Cited by 11
Harnessing immunotherapy to enhance the systemic anti-tumor effects of thermosensitive liposomes
Regenold, M., Wang, X., Kaneko, K., Bannigan, P., & Allen, C. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01272-w · Cited by 11
“Interestingly, in this study, PD-1 blockade therapy showed limited tumor growth inhibition effects when initiated later in the tumor development process [67].”
Background
LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer
Zhao, T., Liu, S., Hanna, N. H., Jalal, S. I., Ding, X., Wan, J., Yan, C., & Du, H. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006272 · Cited by 11
Improving Clinical Islet Transplantation Outcomes
Roep, B. O. (2020) · Diabetes Care · doi:10.2337/dci19-0080 · Cited by 11
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer
Qian, F., & Han, B. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001124 · Cited by 11
“Tumor cells secrete ligands CCL5, CCL7, and CX-C motif chemokine ligand 8, and bind to the receptor CC motif chemokine receptor (CCR) 1 or C-X-C chemokine receptor 2 expressed on the MDSCs subtype to recruit MDSCs into the tumor microenvironment.([34]) Tregs selectively over-express the chemokine CCR4, and its specifi…”
Background
Intermittent fasting suppressed splenic CD205+ G‐MDSC accumulation in a murine breast cancer model by attenuating cell trafficking and inducing apoptosis
Fu, C., Lu, Y., Zhang, Y., Yu, M., Ma, S., & Lyu, S. (2021) · Food Science & Nutrition · doi:10.1002/fsn3.2510 · Cited by 12
“CXCR2 deficiency prevents MDSC trafficking and enhances anti- PD1 efficacy (Highfill et al., 2014).”
Background
Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma
Kim, G. T., Kim, E. Y., Shin, S., Lee, H., Lee, S. H., Sohn, K., & Kim, J. W. (2022) · BMC Cancer · doi:10.1186/s12885-022-09815-7 · Cited by 11
Locoregional therapies combined with immune checkpoint inhibitors for liver metastases
Zhang, X., Zhou, Y., Wei, G.-X., Luo, Y., & Qiu, M. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03484-1 · Cited by 12
“Notably, several MDSC-targeting agents and the blockade of MDSC-inducing cytokines or chemokines have been confirmed to potentiate antitumor immune responses and reverse immune resistance to ICIs in patients with cancer [53–55].”
Background
GLI2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating WNT and Prostaglandin Signaling
DeVito, N. C., Nguyen, Y., Sturdivant, M., Plebanek, M. P., Villarreal, K. A., Yarla, N. S., Jain, V., Aksu, M., Beasley, G. M., Theivanthiran, B., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-1130 · Cited by 11
SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma
Huang, D., Xu, M., Wang, H. Z., Zhao, Y., Zhang, Z., Yu, M., Zhou, M., Pan, J., Zeng, H., Yu, Z., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07779-7 · Cited by 11
“Preclinical ef ﬁ cacy studies showed that myeloid inhibitors can ameliorate the immunosuppressive TME and promote immunotherapy ef ﬁ cacy [9, 10].”
Myeloid Derived Suppressor Cells: Fuel the Fire
Arbab, B. R. A. A. S. (2014) · Biochemistry & Physiology Open Access · doi:10.4172/2168-9652.1000e123 · Cited by 10
“Several of these potential inhibitors have shown the minimal to broad effect on MDSCs [31,33-35].”
Background
Low RECK Expression Is Part of the Cervical Carcinogenesis Mechanisms
Herbster, S., Trombetta-Lima, M., de Souza-Santos, P. T., Paladino, A., Silveira, C. R. F., Sogayar, M. C., Villa, L. L., Lepique, A. P., & Boccardo, E. (2021) · Cancers · doi:10.3390/cancers13092217 · Cited by 10
Inhibition of hexokinase 2 with 3-BrPA promotes MDSCs differentiation and immunosuppressive function
Shi, Z.-Y., Yang, C., Lu, L., Lin, C.-X., Liang, S., Li, G., Zhou, H., & Zheng, J. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104688 · Cited by 10
Cholangiocarcinoma Risk Factors Open the Floodgates for Gut Microbes and Immunosuppressive Myeloid Cells
Chagani, S., & Kwong, L. N. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0187 · Cited by 10
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
Wispelaere, W. D., Annibali, D., Tuyaerts, S., Lambrechts, D., & Amant, F. C. (2021) · Cancers · doi:10.3390/cancers13092040 · Cited by 10
“Accordingly, disrupting CXCR2-mediated MDSC trafficking to the TME was shown to enhance anti-PD-1 therapy response in a murine model of rhabdomyosarcoma [29].”
BackgroundMethod
Emerging mechanisms of immunotherapy resistance in sarcomas
Florou, V., & Wilky, B. A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.111 · Cited by 10
The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies
Holterhus, M., Altvater, B., Kailayangiri, S., & Rössig, C. (2022) · Cancers · doi:10.3390/cancers14092177 · Cited by 10
A checkpoint on innate myeloid cells in pulmonary arterial hypertension
Bryant, A. J., Fu, C., Lu, Y., Brantly, M., Mehrad, B., Moldawer, L. L., Brusko, T. M., Brittain, E. L., West, J. D., Austin, E. D., et al. (2018) · Pulmonary Circulation · doi:10.1177/2045894018823528 · Cited by 9
Mechanism of resistance to immune checkpoint inhibitors
Pandey, M. R., & Ernstoff, M. S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.015 · Cited by 9
“Highfil et al.[71] have shown in a murine model of rhabdomyosarcoma that CXCL-1 and CXCL-2 are responsible for the trafficking of MDSCs into the tumor.”
Background
The sorafenib resistance-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma
Luo, T., Chen, X., Pan, W., Zhang, S., & Huang, J. (2024) · Cell Cycle · doi:10.1080/15384101.2024.2309020 · Cited by 9
“Therefore, the clinical benefits of immune checkpoint therapy in patients with tumors are significantly reduced [49].”
Background
NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer
Ngule, C. M., Shi, R., Ren, X., Jia, H., Oyelami, F., Li, D., Park, Y.-H., Kim, J., Hemati, H., Zhang, Y., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02102-y · Cited by 9
The emerging role of Fusobacteria in carcinogenesis
Gibbs, R. J., Chambers, A., & Hill, D. J. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14353 · Cited by 9
Targeting myeloid cells with platelet-derived extracellular vesicles to overcome resistance of immune checkpoint blockade therapy
Yao, C., Ma, Q., Wang, H., Wu, B., Dai, H., Xu, J., Bai, J., Xu, F., Dube, A., & Wang, C. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123336 · Cited by 9
Targeting CXCR2 in prostate cancer cells can block CD47-SIRPα interaction and reverse M2 macrophage polarization in the TME
Sun, Y., Ren, S.-Q., Wen, W., Jing, J., Luo, X., Shao, S., Duan, R., Zeng, G.-H., & Guo, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02436-1 · Cited by 13
“Emerging studies have shown that CXCR2 blockade can synergize with ICIs to overcome resistance in immunosuppressive tumours [48]– [49].”
GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies
Luo, Y., Xu, H., Zhao, Y., Yang, B., & Zhang, Y. (2025) · Food & Function · doi:10.1039/d5fo03273c · Cited by 9
Hypoxia-induced EGR1 remodels neutrophils to suppress antitumor immunity
Chang, T., Friedman, J., Clavijo, P. E., Robbins, Y. L., Craveiro, M., Huynh, A. P., Dar, M. S., Yang, X., Cao, Y., Sievers, C. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adz2273 · Cited by 9
Mechanisms of Immune Checkpoint Inhibitor Resistance in Hepatocellular Carcinoma and Strategies for Reversal
Dai, X.-Y., Yang, X.-J., Wu, H. M., Lv, Y., & Lan, T. (2025) · Cancers · doi:10.3390/cancers18010039 · Cited by 11
“IL-8 has been demonstrated to recruit MDSCs and enhance immune escape in cancer via C-X-C motif chemokine receptor 2 (CXCR2) signaling [178].”
Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress
Andrés, C., de la Lastra, J. M. P., Juan, C., Plou, F. J., & Pérez‐Lebeña, E. (2023) · Vaccines · doi:10.3390/vaccines11020218 · Cited by 9
Novel Function of Cancer Stem Cell Marker ALDH1A3 in Glioblastoma: Pro-Angiogenesis through Paracrine PAI-1 and IL-8
Chen, Z., Will, R. D., Kim, S. N., Busch, M. A., Dünker, N., Dammann, P. R., Sure, U., & Zhu, Y. (2023) · Cancers · doi:10.3390/cancers15174422 · Cited by 9
Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies
Amaya, C. N., Wians, F. H., Bryan, B. A., & Torabi, A. (2017) · Pathology · doi:10.1016/j.pathol.2016.10.015 · Cited by 9
Chrysin targets myeloid‐derived suppressor cells and enhances tumour response to anti‐PD‐1 immunotherapy
Li, Y., Ru, Y., Huang, X., Chen, C., Dou, D., Wang, Q., Wu, X., Liu, H., & Sun, T. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1019 · Cited by 9
The soldiers needed to be awakened: Tumor-infiltrating immune cells
Yaping, W., Wang, Z., Zhuling, C., Li, R., Pengyu, F., Lili, G., Cheng, J., Bo, Z., Liu, L., Guangdong, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.988703 · Cited by 9
“Targeting CXCR2 also augments the therapeutic efficacy of PD-1 blockade (Highfill et al., 2014; Zhang et al., 2020).”
Background
Suppressive myeloid cells in SARS-CoV-2 and Mycobacterium tuberculosis co-infection
Shaw, J., Malherbe, S. T., Walzl, G., & du Plessis, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1222911 · Cited by 8
SQLE-mediated squalene metabolism promotes tumor immune evasion in pancreatic cancer
Pan, J., Liang, H.-X., Zhou, L., Lu, W., Huo, B.-T., Liu, R., & Huang, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512981 · Cited by 9
Recurrent and Metastatic Head and Neck Cancer: Mechanisms of Treatment Failure, Treatment Paradigms, and New Horizons
Barham, W. T., Stagg, M. P., Mualla, R., Dileo, M. D., & Kansara, S. (2025) · Cancers · doi:10.3390/cancers17010144 · Cited by 8
“For example, the inhibition of myeloid-derived suppressor cells (MDSCs) from interacting with tumor cells may increase the efficacy of immune checkpoint blockade by preventing MDSCs (and associated chemokines) from participating in tumor cell invasion, angiogenesis, and further metastasis [70,71].”
CCL20/CXCL5 Drives Crosstalk Between Anaplastic Thyroid Cancer Stem Cells and Tumor‐Associated Macrophages to Promote Tumor Progression
Liu, Q., Wang, Y., Song, M., Huang, J., Shi, J., Sun, W., Ji, X., Chang, Y., Ma, B., Zhang, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202405399 · Cited by 8
Self-citation
Subtypes of tumor-associated neutrophils and their roles in cancer immunotherapy
Chu, X., Pu, N., Yang, X., Xie, Y., Liu, L., & Jin, Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104763 · Cited by 8
Phenotypic and Functional Diversity of Neutrophils in Gut Inflammation and Cancer
Sumagin, R. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.10.009 · Cited by 8
Small Molecular Immune Modulators as Anticancer Agents
Han, Y., Zhu, L., Wu, W., Zhang, H., Hu, W., Dai, L., & Yang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_22 · Cited by 8
Self-citation
Human innate immune cell crosstalk induces melanoma cell senescence
Funck, F., Pahl, J. H. W., Kyjacová, L., Freund, L., Oehrl, S., Gräbe, G., Pezer, S., Hassel, J. C., Sleeman, J. P., Cerwenka, A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1808424 · Cited by 9
Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors
Oyanagi, J., Koh, Y., Sato, K., Teraoka, S., Tokudome, N., Hayata, A., Akamatsu, H., Ozawa, Y., Nakanishi, M., Ueda, H., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.007 · Cited by 7
Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma
Teshima, T., Kobayashi, Y., Kawai, T., Kushihara, Y., Nagaoka, K., Miyakawa, J., Akiyama, Y., Yamada, Y., Sato, Y., Yamada, D., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13384 · Cited by 7
“A previous study with murine rhabdomyosarcoma showed that CXCR2‐positive MDSCs inhibited the antitumor effect of anti‐PD‐1 antibody treatment and that anti‐CXCR2 monoclonal antibody therapy enhanced it (30,31).”
Background
Regramming myeloid responses to improve cancer immunotherapy
Zhu, Y., Hawkins, W. G., & DeNardo, D. G. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.974399 · Cited by 8
Decitabine suppresses MDSC-induced immunosuppression through dual functional mechanism and inhibits melanoma metastasis
Zhang, Z., Wang, T., Fang, G., Xiao, X., Zhang, Z., & Zhao, J. (2024) · Medical Oncology · doi:10.1007/s12032-024-02320-w · Cited by 7
“Third, Dec notably decreased vegf, and Cxcr2 gene expression, limiting MDSC migration from bone marrow to tumors [32].”
Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management
Baldi, S., Alnaggar, M., AL-Mogahed, M., Khalil, K., & Zhan, X. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00403-w · Cited by 8
“Many tumors with a so-called “cold” TME (i.e., low immune infiltration in the [ 45 , 46 ] microenvironment) are typically non-responsive to ICIs, even when TMB levels are high [56].”
Novel Therapeutics and the Path Toward Effective Immunotherapy in Malignant Peripheral Nerve Sheath Tumors
Lingo, J. J., Elias, E. C., & Quelle, D. E. (2025) · Cancers · doi:10.3390/cancers17142410 · Cited by 9
“In rhabdomyosarcoma (RMS), inhibiting the trafficking of myeloid-derived suppressor cells (MDSCs) alleviates resistance to and synergizes with anti-PD-1 therapy [75].”
A novel CXCL8 analog is effective in inhibiting the growth via cell cycle arrest and attenuating invasion of Lewis lung carcinoma
Hsu, S.-Y., Yu, H., Lee, W.-C., Hsiao, C.-E., Wu, C., Cheng, H.-T., Lin, L., Li, F., Chou, Y., & Cheng, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s215824 · Cited by 7
Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen
Bujanda, Z. A. L., Chaimowitz, M. G., Armstrong, T. D., Foote, J. B., Emens, L. A., & Drake, C. G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1809926 · Cited by 7
“In line with this hypothesis, we and others have demonstrated that blocking PMN-MDSC trafficking into the tumor augments responses to immune checkpoint blockade.(34,37) In addition, the rationale for targeting these cells in combination with other immune therapeutic interventions has also been supported by studies usi…”
Background
Potential Strategies to Improve the Effectiveness of Drug Therapy by Changing Factors Related to Tumor Microenvironment
Cao, D., Naiyila, X., Li, J., Huang, Y. C., Chen, Z., Chen, B., Li, J., Guo, J., Dong, Q., Ai, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.705280 · Cited by 7
Myeloid-derived suppressor cells (MDSCs): what do we currently know about the effect they have against anti-PD-1/PD-L1 therapies?
Tellez, R. S. L., Reynolds, L., & Piris, M. A. (2023) · ecancermedicalscience · doi:10.3332/ecancer.2023.1556 · Cited by 7
Combining Chemotherapy and Checkpoint Blockade in Thoracic Cancer: How to Proceed?
Aston, W. J., Fisher, S. A., Khong, A., Mok, L. C., Nowak, A. K., Lake, R., & Lesterhuis, W. J. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.37 · Cited by 7
CCMAlnc Promotes the Malignance of Colorectal Cancer by Modulating the Interaction Between miR-5001-5p and Its Target mRNA
Yan, Y., Xuan, B., Gao, Z., Shen, C., Cao, Y., Hong, J., Chen, H., Cui, Z., Ye, G., Fang, J., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.566932 · Cited by 7
Host ANGPTL2 establishes an immunosuppressive tumor microenvironment and resistance to immune checkpoint therapy
Yumoto, S., Horiguchi, H., Kadomatsu, T., Horino, T., Sato, M., Terada, K., Miyata, K., Moroishi, T., Baba, H., & Oike, Y. (2024) · Cancer Science · doi:10.1111/cas.16348 · Cited by 6
Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints
Dai, Y., Dong, C., Wang, Z., Zhou, Y., Wang, Y., Hao, Y., Chen, P., Liang, C., & Li, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1482291 · Cited by 6
Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer
Christopher, B. N., Golick, L., Basar, A., Reyes, L., Robinson, R. M., Angerstein, A. O., Krieg, C., Hobbs, G. A., D, D. C. G., O’Bryan, J. P., et al. (2025) · Biomolecules · doi:10.3390/biom15050645 · Cited by 6
“The expression of CXCR2 on MDSCs is critical for their recruitment to the PDAC TME [29].”
Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors
Zhang, Y., Fu, X., Zhang, L., Zhou, Q., & Wang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1598484 · Cited by 6
Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre‐clinical models
Jessel, M.-D., McGreevy, O., McReynolds, L., Dahal, L. N., Gilbert, T. M., Malik, H., Goldring, C. E., & Randle, L. E. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70057 · Cited by 6
“58,59 TANs exhibit functional plasticity, adopting either pro-tumor (N2) or antitumor (N1) phenotypes.”
Improving therapeutic resistance: beginning with targeting the tumor microenvironment
Guan, X., Guan, X., & Jiao, Z. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.2011661 · Cited by 6
Beyond the horizon: Neutrophils leading the way in the evolution of immunotherapy
Rajgopal, S., Nakano, K., & Cook, L. M. (2023) · Cancer Medicine · doi:10.1002/cam4.6761 · Cited by 5
Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer
Litman‐Zawadzka, A., Łukaszewicz‐Zając, M., Gryko, M., Kulczyńska‐Przybik, A., Kędra, B., & Mroczko, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176193 · Cited by 6
“It has been shown that CXCR2 is a pro-tumorigenic chemokine receptor that might induce inflammation in the tumor microenvironment [9,10].”
Background
Upcoming immunotherapeutic combinations for B-cell lymphoma
Greve, P. F., Meyer‐Wentrup, F. A. G., Peperzak, V., & Boes, M. L. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab001 · Cited by 6
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Salkeni, M. A., Shin, J. Y., & Gulley, J. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_2 · Cited by 6
The Dark Knight: Functional Reprogramming of Neutrophils in the Pathogenesis of Colitis-Associated Cancer
Ghosh, S., & Zanoni, I. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0642 · Cited by 6
Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
Chew, H. Y., Chan, V., Simpson, F., & Dolcetti, R. (2020) · Cancers · doi:10.3390/cancers12113392 · Cited by 6
The Immune Profile of EGFR -Mutated Non-Small-Cell Lung Cancer at Disease Onset and Progression after Tyrosine Kinase Inhibitors Therapy
Fumagalli, C., Guerini‐Rocco, E., Vacirca, D., Passaro, A., de Marinis, F., & Barberis, M. C. P. (2018) · Immunotherapy · doi:10.2217/imt-2018-0027 · Cited by 6
Isolation of myeloid-derived suppressor cells subsets from spleens of orthotopic liver cancer-bearing mice by fluorescent-activated and magnetic-activated cell sorting: similarities and differences.
Xu, Y., Zhao, W., Wu, D., Xu, J., Lin, S., Tang, K., Yin, Z., & Wang, X. (2014) · Europe PMC (PubMed Central) · Cited by 6
Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy
Podder, V., Coleman, R. L., Eskander, R. N., Flint, M., Monk, B. J., & Slomovitz, B. M. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.102124 · Cited by 5
Mechanistic roles and intervention strategies involving gut microbiota, amino acid metabolism, and the tumor immune microenvironment in MAFLD-HCC progression
Guo, Z., Yao, Z., Chen, X., Wu, D., Ouyang, Y., Shen, Y., Wang, Y., Zhang, H., Lu, Y., & Lv, W. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01906-6 · Cited by 5
Self-citation
Defining the marker and developmental trajectory of myeloid-derived suppressor cells in aging by single-cell transcriptomics
Su, Y., Wu, R., Ai, H., Zhong, Z., Zou, L., Wang, Z., Tu, K., Tang, L., Gao, J., Huang, Y., et al. (2025) · npj Aging · doi:10.1038/s41514-025-00317-x · Cited by 5
Self-citation
Cannabidiol suppresses emergency MDSCs generation by disturbing EEF1B2-mediated C/EBP β protein synthesis in colorectal adenomas
Pan, J., Zhao, L., Du, H., Zhu, Y., Sun, X., Xu, Q., Cheng, H., Chen, H., & Sun, Y. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013081 · Cited by 5
“The mechanisms of MDSCs recruited to the tumor or inflammation site are widely reported, 27–29 but how the differentiation of MDSCs is affected and how to regulate the generation of MDSCs from their original bone narrow are not clear.”
Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations
Fatahichegeni, M., Ansarian, M. A., Xiao, M., Gao, W., & Shi, R. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04384-1 · Cited by 5
“Human pediatric sarcoma patients with elevated serum CXCR2 ligands (including CXCL8) have decreased survival, and MDSC accumulation in the tumor bed limits the efficacy of immunotherapy [45].”
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
Shah, M., Hussain, M. S., & Woo, H. G. (2025) · Genomics & Informatics · doi:10.1186/s44342-024-00033-0 · Cited by 6

Authors: Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L.
Affiliations: National Institutes of Health (US)
Corresponding author: Mackall, Crystal L.
ORCID: Highfill, Steven L.
Cui, Yongzhi
Giles, Amber J.
Zhang, Hua
Kaplan, Rosandra N.
Mackall, Crystal L.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2014-05-21
Volume: 6
Issue: 237
Pages: 237ra67-237ra67
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.3007974
PMC: PMC6980372
OpenAlex: W2171524684
Cited by: 767
References: 50
Citations by year: 2026: 55 · 2025: 62 · 2024: 57 · 2023: 83 · 2022: 73 · 2021: 100 · 2020: 91 · 2019: 60 · 2018: 52 · 2017: 52 · 2016: 38 · 2015: 31 · 2014: 12
FWCI: 20.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01BC011072, Z01BC010566, Z01SC010289)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
Keywords: CXCR2, myeloid-derived suppressor cells, tumor immune evasion, anti-PD-1 therapy, rhabdomyosarcoma, pediatric sarcoma, interleukin-8, PD-L1, tumor immunosuppression
MeSH terms: Adolescent, Adult, Animals, Antibodies, Monoclonal, Antigens, Ly, Antineoplastic Combined Chemotherapy Protocols, Chemotaxis, Child, Child, Preschool, Female, Humans, Male, Mice, Inbred C57BL, Prognosis, Rhabdomyosarcoma, Time Factors, Neoplastic Stem Cells, Case-Control Studies, Cytokines, Interleukin-8, Mice, Knockout, Tumor Escape, Receptors, Interleukin-8B, CD11b Antigen, Cell Line, Tumor, Tumor Burden, Mice, Chemokine CXCL1, Young Adult, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks